Martinón-Torres Federico, Bouzón Alejandro Marta, Redondo Collazo Lorenzo, Sánchez Lastres Juan Manuel, Pértega Díaz Sonia, Seoane Pillado Ma Teresa, Martinón Sánchez José María
Área de Pediatría, Hospital Clínico Universitario de Santiago de Compostela, Spain.
Hum Vaccin. 2011 Jul;7(7):757-61. doi: 10.4161/hv.7.7.15576. Epub 2011 Jul 1.
With the aim of determining rotavirus vaccine effectiveness (RVVE) in Spain, from Oct-2008/Jun-2009, 467 consecutive children below 2 years old with acute gastroenteritis (AGE) were recruited using a pediatric research network (ReGALIP-www.regalip.org) that includes primary, emergency and hospital care settings. Of 467 enrolled children, 32.3% were rotavirus positive and 35.0% had received at least one dose of any rotavirus vaccine. RRVE to prevent any episode of rotavirus AGE was 91.5% (95% CI: 83.7%-95.6%). RVVE to prevent hospitalization by rotavirus AGE was 95.6% (85.6-98.6%). No differences in RVVE were found regarding the vaccine used. Rotavirus vaccines have showed an outstanding effectiveness in Spain.
为确定西班牙轮状病毒疫苗的有效性（RVVE），从2008年10月至2009年6月，利用一个涵盖初级、急诊和医院护理机构的儿科研究网络（ReGALIP - www.regalip.org）招募了467名2岁以下患有急性胃肠炎（AGE）的连续儿童。在467名登记儿童中，32.3%轮状病毒呈阳性，35.0%至少接种过一剂任何轮状病毒疫苗。预防任何轮状病毒AGE发作的RRVE为91.5%（95%CI：83.7% - 95.6%）。预防因轮状病毒AGE住院的RVVE为95.6%（85.6 - 98.6%）。在所使用的疫苗方面，未发现RVVE有差异。轮状病毒疫苗在西班牙已显示出卓越的有效性。
